TeraPore Technologies develops high-permeability, high-resolution membrane nanofiltration systems for bioprocessing, centered on its Intelligent Membrane platform. Its technology features a tunable chemical structure and uniform nanoscale pore sizes designed to address difficult bioseparation challenges. The company is launching its IsoBlock™ virus filter family, engineered for high productivity and robust viral clearance across development, clinical trials, and production. TeraPore aims to expand the use of its core technology into new high-value markets and contamination-control applications. The company is venture-backed and has received grant funding from NSF, NIH, and the Defense Threat Reduction Agency. It will use the new financing to commercialize IsoBlock filters and broaden market deployment. TeraPore Technologies develops and manufactures advanced nanofiltration membrane systems using a proprietary block copolymer self-assembly technology. The polymers spontaneously form highly uniform structures that create precise nanoscale pores when fabricated into membranes. Its membranes target critical bioprocess applications, notably the separation of viral contaminants in biologics production. The company is led by founder and CEO Dr. Rachel Dorin and was founded in 2013 as a Cornell University spinout. TeraPore is based in South San Francisco, CA, and has received support from the NIH, NSF and DTRA. It intends to use the Series A proceeds to accelerate product development and commercialization efforts.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2023